Retrospective Pharmacotherapeutic Evaluation of Dutasteride Not Approved by US FDA for Androgenetic Alopecia in Korea

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This review found that while finasteride may improve female pattern hair loss and hirsutism in women, more long-term studies are needed to optimize its use and assess potential consequences.

This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This study found that despite only topical minoxidil and oral finasteride being approved for androgenetic alopecia in Spain, dermatologists commonly prescribe various off-label treatments for both male and female patients.

This study found that low-level laser therapy was the most effective non-surgical treatment for androgenetic alopecia, although the overall quality of evidence supporting various therapies was generally low.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

In this study, 68% of patients treated with finasteride showed improved hair growth in male androgenetic alopecia, compared to 38% with Serenoa repens, indicating finasteride's superior efficacy.

This study found that adding low-dose dutasteride to ongoing finasteride treatment significantly improved hair density in a patient with androgenetic alopecia.

This study confirmed that 5% topical minoxidil is more effective than 1% in increasing hair density in Japanese men with androgenetic alopecia, with no significant difference in adverse event rates.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This webpage provides access options for JAMA Dermatology but does not contain research findings or results.